Celltrion Antibody Treatment 'Rekkirona Joo' Supplied to Medical Institutions Starting the 17th

Reckonaju, a COVID-19 antibody treatment, is being produced at Celltrion's second plant in Yeonsu-gu, Incheon. [Image source=Yonhap News]

[Asia Economy Reporter Lee Chun-hee] Celltrion's 'Rekkironaju (CT-P59)', the first domestically approved conditional COVID-19 antibody treatment, will be supplied to medical institutions starting from the 17th.

The Central Disease Control Headquarters announced on the 15th that 'Rekkironaju 960mg (Regdanvimab)' will be temporarily purchased directly and supplied to medical institutions from the 17th.

The treatment recipients are based on the scope approved by the Ministry of Food and Drug Safety. They are COVID-19 confirmed patients within 7 days of symptom onset, who do not require oxygen therapy, and are either aged 60 or older, have underlying conditions such as cardiovascular disease, chronic respiratory disease, diabetes, hypertension, or have pneumonia.

The treatment is provided free of charge and can be supplied upon application by the medical institution to the pharmaceutical company.

Detailed information regarding the supply of the treatment will be separately announced through each city and province on the same day. Medical institutions can apply from the 16th, and supply will begin on the 17th.

Kim Gang-rip, Commissioner of the Ministry of Food and Drug Safety (right), is examining a sample of the COVID-19 antibody treatment "Rekkirona-ju" during an on-site inspection of the COVID-19 antibody treatment production at Celltrion's second plant in Yeonsu-gu, Incheon, on the afternoon of the 8th. On the left is Seo Jung-jin, Chairman of the Celltrion Group. [Image source=Yonhap News]

This content was produced with the assistance of AI translation services.